- 3rd generation recombinant immunotoxins (RITs), following the ADC generation (antibody‑drug conjugates): RITs are fusion proteins connecting a short targeting fragment of an antibody and a truncated form of a toxin, extensively sought for targeted therapies in oncology (solid tumors, leukemia), also against intestinal and pulmonary pathogens, with potential against autoimmune diseases, Parkinson's, among other illnesses.
These biologics are called “hostile” or “recalcitrant” because of the great difficulties to produce toxic high‑potency compounds in classical cell systems, which is by far much easier in (micro‑)vegetal cells.
- Anti‑infective fusion proteins, purified or preferably vectored (new generation AMPs). They help counteract the increasing resistance of bacteria to antibiotics, neutralize the action of viruses through innovative mechanisms.
- Antigenic vaccines, vectored in particular for oral and intranasal delivery. The compartmentalization inside the cell brings increased thermostability, a remarkable logistical and economical advantage, facilitating wider access, and particularly relevant to developing countries.
Compared to animal cells, yeasts, prokaryotic bacteria and higher plants, the competitive advantages of our microalgae cell lines are:
► ability to produce toxic ("recalcitrant") molecules
► a rather "easy" extrapolation of a unicellular system
► excellent product homogeneity (intra- and inter‑lot consistency)
► possibility of non‑parenteral modes of administration
► thermal stabilization, thus a simpler lighter supply chain
In addition, this system will respond very significantly to the challenge of reducing production costs.
It can be further extended to other domains with different molecules: N- and O‑glycosylated proteins, monoclonal antibodies, etc.